Margaret Kyle
Margaret Kyle

STRATEGY
Visiting Professor of Strategy

Print Overview

Margaret Kyle (Toulouse School of Economics and IDEI) studies innovation, productivity and competition.  She has a number of papers examining R&D productivity in the pharmaceutical industry, specifically the role of geographic and academic spillovers; the firm-specific and policy determinants of the diffusion of new products; generic competition; and the use of markets for technology.  Recent work examines the effect of trade and IP policies on the level, location and direction of R&D investment and competition. She also works on issues of innovation and access to therapies in developing countries. Her papers have been published in various journals of economics, strategy, and health policy, including the RAND Journal of Economics, Review of Economics and Statistics, Journal of Law and Economics, Strategic Management Journal, Health Services Research, and Health Affairs.

Margaret holds a PhD in economics from the Massachusetts Institute of Technology.  She previously held positions at Carnegie Mellon University, Duke University and London Business School.  She has also been a visiting scholar at the Center for the Study of Innovation and Productivity at the Federal Reserve Bank of San Francisco and at the University of Hong Kong.  She is a Research Associate at the Centre for Economic Policy Research.

Print Vita
Education
Ph.D., 2002, Economics, Massachusetts Institute of Technology, Massachusetts Institute of Technology
B.S. , 1995, Economics, Cornell University, Cornell University, Honors

Academic Positions
Professeur, Institut d'Administration des Enterprises, Universite de Toulouse 1 and Toulouse School of Economics, 2010-present
Visiting Professor, University of Hong Kong, 2013-2013
Professeur associe, Universit e de Toulouse 1 and Toulouse School of Economics, 2009-2010
Assistant Professor, London Business School, 2006-2010
Assistant Professor, Fuqua School of Business, Duke University, 2004-2006
Assistant Professor, Tepper School of Business, Carnegie Mellon University, 2002-2004

Other Professional Experience
Research Assistant, Board of Governors of the Federal Reserve System, 1995-1997

 
Print Research
Research Interests
Industrial Organization, Productivity, Economics of Innovation, Health Policy, Business Strategy


 
Print Teaching
Other
Pharmaceutical Strategy (HEMA-931-B)
The pharmaceutical industry is a large, global and innovative sector. Advances in science and technology have required substantial changes to the organization and orientation of pharmaceutical firms. It has experienced substantial consolidation, entry by small, focused firms, and growth in specialized firms such as contract research organizations. The industry is also highly regulated, with many country-specific laws and policies. These features pose important challenges to the management of global firms. Each class meeting will include lecture material and a case discussion. The purpose of these sessions is to provide an overview of the institutional environment and "stylized facts" about pharmaceutical markets.

Full-Time / Part-Time MBA
Technology and Innovation Strategy (MGMT-463-0)

This course counts toward the following majors: Entrepreneurship & Innovation, Management & Strategy, Media Management

This course develops approaches to analyzing strategies within technology markets. It teaches students how to analyze commercial forces in hyper-competitive markets, where firm structure, product cycles and competitive environment change rapidly. The course asks students to develop strategies that align with these structural market forces. These issues are illustrated through general readings and with cases from computing, electronics, online, biotechnology and pharmaceuticals markets. The course strikes a balance between presenting a few general models of market behavior and presenting a few key episodes of market behavior. It is aimed at three types of students: those who anticipate taking management positions in technology-intensive firms where they must formulate strategy, those who anticipate investing in technology markets and must analyze firm strategy, and those who anticipate contracting with firms that do much of their business in these types of markets.